Published 2025-02-01
“…Xiuqi
Li,1,* Shupeng Liu,1,* Mengyang Yu,1 Wanlin Xi,1 Xiaofei Wu,1 Dan Liu,2 Aijing Liu,1
Hongyun Wang1 1Clinical Pharmacology Research Center, Peking Union Medical College Hospital, NMPA Key Laboratory for Clinical Research and Evaluation of Drug, Beijing Key Laboratory of Clinical PK & PD Investigation for Innovative Drugs, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, People’s Republic of China; 2School of Life Science and Biopharmaceuticals, Shenyang Pharmaceutical University, Shenyang, Liaoning, 110000, People’s Republic of China*These authors contributed equally to this workCorrespondence:
Hongyun Wang, Email wanghy@pumch.cnBackground: Proton pump inhibitors (PPIs) and potassium competitive acid blockers (P-CABs) are widely used to treat acid-related diseases (ARDs). …”
Get full text
Article